Table 4.

Guideline concordant primary treatment and race/ethnicity by breast cancer subtypes

	Non-Hispanic white	African American		Hispanic white		Asian/Pacific Islander		American Indian/Alaska Native
	n = 26,980	n = 3,380		n = 3,428		n = 3,066		n = 199
	n (%)	n (%)	OR (95% CI)	n (%)	OR (95% CI)	n (%)	OR (95% CI)	n (%)	OR (95% CI)
All subtypes^a
Concordant	23,538 (87.2)	2,774 (82.1)	Ref	2,882 (84.1)	Ref	2,691 (87.8)	Ref	168 (84.4)	Ref
Nonconcordant	3,442 (12.8)	606 (17.9)	1.4 (1.3–1.6)	546 (15.9)	1.3 (1.2–1.4)	375 (12.2)	1.0 (0.9–1.1)	31 (15.6)	1.3 (0.9–1.9)
HR⁺/HER2⁻^b
Concordant	18,994 (88.1)	1,926 (84.4)	Ref	2,220 (85.4)	Ref	2,104 (88.5)	Ref	140 (84.3)	Ref
Nonconcordant	2,577 (11.9)	357 (15.6)	1.3 (1.2–1.5)	380 (14.6)	1.3 (1.1–1.4)	275 (11.5)	1.0 (0.8–1.1)	26 (15.7)	1.3 (0.9–2.1)
Triple negative^b
Concordant	1,862 (83.2)	447 (75.1)	Ref	282 (80.6)	Ref	174 (86.6)	Ref	7 (77.8)	Ref
Nonconcordant	376 (16.8)	148 (24.9)	1.6 (1.3–2.0)	68 (19.4)	1.2 (0.9–1.6)	27 (13.4)	0.8 (0.5–1.2)	2 (22.2)	1.5 (0.3–7.1)
HR⁺/HER2⁺^b
Concordant	1,951 (84.3)	277 (79.6)	Ref	269 (79.1)	Ref	268 (83.0)	Ref	14 (82.4)	Ref
Nonconcordant	363 (15.7)	71 (20.4)	1.4 (1.0–1.8)	71 (20.9)	1.4 (1.1–1.9)	55 (17.0)	1.1 (0.8–1.5)	3 (17.6)	1.2 (0.3–4.1)
HR⁻/HER2⁺^b
Concordant	731 (85.3)	124 (80.5)	Ref	111 (80.4)	Ref	145 (89.0)	Ref	7 (100.0)	NA
Nonconcordant	126 (14.7)	30 (19.5)	1.4 (0.9–2.2)	27 (19.6)	1.5 (0.9–2.4)	18 (11.0)	0.7 (0.4–1.2)	0 (0.0)

↵^aORs adjusted for age groups, stage (I vs. II), and breast cancer subtypes.
↵^bORs adjusted for age and stage (I vs. II). ORs are in bold if P values are <0.05.